Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

Dejan Juric, Ian Krop, Ramesk K Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra M. Sanabria Bohorquez, Heidi M. Savage, Deepak Sampath, Laurent Salphati, Ray S. Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3–16 mg taselisib once-daily capsule). Taselisib pharmacokinetics were dose-proportional; mean half-life was 40 hours. Frequent dose-dependent, treatment-related adverse events included diarrhea, hyperglycemia, decreased appetite, nausea, rash, stomatitis, and vomiting. At 12 and 16 mg dose levels, dose-limiting toxicities (DLT) were observed, with an accumulation of higher-grade adverse events after the cycle 1 DLT assessment window. Pharmacodynamic findings showed pathway inhibition at3 mg in patient tumor samples, consistent with preclinical PIK3CA-mutant tumor xenograft models. Confirmed response rate was 36% for PIK3CA-mutant tumor patients with measurable disease [5/14: 4 breast cancer (3 patients at 12 mg); 1 non–small cell lung cancer], where responses started at 3 mg, and 0% in patients with tumors without known PIK3CA hotspot mutations (0/15). Significance: Preliminary data consistent with preclinical data indicate increased antitumor activity of taselisib in patients with PIK3CA -mutant tumors (in comparison with patients with tumors without known activating PIK3CA hotspot mutations) starting at the lowest dose tested of 3 mg, thereby supporting higher potency for taselisib against PIK3CA -mutant tumors.

Original languageEnglish (US)
Pages (from-to)704-715
Number of pages12
JournalCancer Discovery
Volume7
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Phosphatidylinositol 3-Kinases
Neoplasms
Growth Inhibitors
Stomatitis
Mutation
Appetite
Exanthema
Heterografts
Non-Small Cell Lung Carcinoma
Hyperglycemia
Nausea
Capsules
Vomiting
Half-Life
Diarrhea
Pharmacokinetics

ASJC Scopus subject areas

  • Oncology

Cite this

Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. / Juric, Dejan; Krop, Ian; Ramanathan, Ramesk K; Wilson, Timothy R.; Ware, Joseph A.; Sanabria Bohorquez, Sandra M.; Savage, Heidi M.; Sampath, Deepak; Salphati, Laurent; Lin, Ray S.; Jin, Huan; Parmar, Hema; Hsu, Jerry Y.; Von Hoff, Daniel D.; Baselga, José.

In: Cancer Discovery, Vol. 7, No. 7, 01.07.2017, p. 704-715.

Research output: Contribution to journalArticle

Juric, D, Krop, I, Ramanathan, RK, Wilson, TR, Ware, JA, Sanabria Bohorquez, SM, Savage, HM, Sampath, D, Salphati, L, Lin, RS, Jin, H, Parmar, H, Hsu, JY, Von Hoff, DD & Baselga, J 2017, 'Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors', Cancer Discovery, vol. 7, no. 7, pp. 704-715. https://doi.org/10.1158/2159-8290.CD-16-1080
Juric, Dejan ; Krop, Ian ; Ramanathan, Ramesk K ; Wilson, Timothy R. ; Ware, Joseph A. ; Sanabria Bohorquez, Sandra M. ; Savage, Heidi M. ; Sampath, Deepak ; Salphati, Laurent ; Lin, Ray S. ; Jin, Huan ; Parmar, Hema ; Hsu, Jerry Y. ; Von Hoff, Daniel D. ; Baselga, José. / Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. In: Cancer Discovery. 2017 ; Vol. 7, No. 7. pp. 704-715.
@article{6e0b4cc023a54d4a9d2d0b915ef37699,
title = "Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors",
abstract = "Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3–16 mg taselisib once-daily capsule). Taselisib pharmacokinetics were dose-proportional; mean half-life was 40 hours. Frequent dose-dependent, treatment-related adverse events included diarrhea, hyperglycemia, decreased appetite, nausea, rash, stomatitis, and vomiting. At 12 and 16 mg dose levels, dose-limiting toxicities (DLT) were observed, with an accumulation of higher-grade adverse events after the cycle 1 DLT assessment window. Pharmacodynamic findings showed pathway inhibition at≥3 mg in patient tumor samples, consistent with preclinical PIK3CA-mutant tumor xenograft models. Confirmed response rate was 36{\%} for PIK3CA-mutant tumor patients with measurable disease [5/14: 4 breast cancer (3 patients at 12 mg); 1 non–small cell lung cancer], where responses started at 3 mg, and 0{\%} in patients with tumors without known PIK3CA hotspot mutations (0/15). Significance: Preliminary data consistent with preclinical data indicate increased antitumor activity of taselisib in patients with PIK3CA -mutant tumors (in comparison with patients with tumors without known activating PIK3CA hotspot mutations) starting at the lowest dose tested of 3 mg, thereby supporting higher potency for taselisib against PIK3CA -mutant tumors.",
author = "Dejan Juric and Ian Krop and Ramanathan, {Ramesk K} and Wilson, {Timothy R.} and Ware, {Joseph A.} and {Sanabria Bohorquez}, {Sandra M.} and Savage, {Heidi M.} and Deepak Sampath and Laurent Salphati and Lin, {Ray S.} and Huan Jin and Hema Parmar and Hsu, {Jerry Y.} and {Von Hoff}, {Daniel D.} and Jos{\'e} Baselga",
year = "2017",
month = "7",
day = "1",
doi = "10.1158/2159-8290.CD-16-1080",
language = "English (US)",
volume = "7",
pages = "704--715",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

AU - Juric, Dejan

AU - Krop, Ian

AU - Ramanathan, Ramesk K

AU - Wilson, Timothy R.

AU - Ware, Joseph A.

AU - Sanabria Bohorquez, Sandra M.

AU - Savage, Heidi M.

AU - Sampath, Deepak

AU - Salphati, Laurent

AU - Lin, Ray S.

AU - Jin, Huan

AU - Parmar, Hema

AU - Hsu, Jerry Y.

AU - Von Hoff, Daniel D.

AU - Baselga, José

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3–16 mg taselisib once-daily capsule). Taselisib pharmacokinetics were dose-proportional; mean half-life was 40 hours. Frequent dose-dependent, treatment-related adverse events included diarrhea, hyperglycemia, decreased appetite, nausea, rash, stomatitis, and vomiting. At 12 and 16 mg dose levels, dose-limiting toxicities (DLT) were observed, with an accumulation of higher-grade adverse events after the cycle 1 DLT assessment window. Pharmacodynamic findings showed pathway inhibition at≥3 mg in patient tumor samples, consistent with preclinical PIK3CA-mutant tumor xenograft models. Confirmed response rate was 36% for PIK3CA-mutant tumor patients with measurable disease [5/14: 4 breast cancer (3 patients at 12 mg); 1 non–small cell lung cancer], where responses started at 3 mg, and 0% in patients with tumors without known PIK3CA hotspot mutations (0/15). Significance: Preliminary data consistent with preclinical data indicate increased antitumor activity of taselisib in patients with PIK3CA -mutant tumors (in comparison with patients with tumors without known activating PIK3CA hotspot mutations) starting at the lowest dose tested of 3 mg, thereby supporting higher potency for taselisib against PIK3CA -mutant tumors.

AB - Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3–16 mg taselisib once-daily capsule). Taselisib pharmacokinetics were dose-proportional; mean half-life was 40 hours. Frequent dose-dependent, treatment-related adverse events included diarrhea, hyperglycemia, decreased appetite, nausea, rash, stomatitis, and vomiting. At 12 and 16 mg dose levels, dose-limiting toxicities (DLT) were observed, with an accumulation of higher-grade adverse events after the cycle 1 DLT assessment window. Pharmacodynamic findings showed pathway inhibition at≥3 mg in patient tumor samples, consistent with preclinical PIK3CA-mutant tumor xenograft models. Confirmed response rate was 36% for PIK3CA-mutant tumor patients with measurable disease [5/14: 4 breast cancer (3 patients at 12 mg); 1 non–small cell lung cancer], where responses started at 3 mg, and 0% in patients with tumors without known PIK3CA hotspot mutations (0/15). Significance: Preliminary data consistent with preclinical data indicate increased antitumor activity of taselisib in patients with PIK3CA -mutant tumors (in comparison with patients with tumors without known activating PIK3CA hotspot mutations) starting at the lowest dose tested of 3 mg, thereby supporting higher potency for taselisib against PIK3CA -mutant tumors.

UR - http://www.scopus.com/inward/record.url?scp=85018510810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018510810&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-1080

DO - 10.1158/2159-8290.CD-16-1080

M3 - Article

C2 - 28331003

AN - SCOPUS:85018510810

VL - 7

SP - 704

EP - 715

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 7

ER -